DOCSLIB.ORG

Antidepressant Medications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antidepressant Medications Antidepressant Medications These medicines help balance chemicals in the brain to treat mood problems and manage other conditions. There are different types of antidepressant medicines. Some of the most common ones are listed below. Check the name of the medicine(s) you take: SSRIs (selective serotonin reuptake inhibitors): MAOIs (monoamine oxidase inhibitors): Citalopram (Celexa) Isocarboxazid (Marplan) Escitalopram (Lexapro) Phenelzine (Nardil) Fluoxetine (Prozac) Tranylcypromine (Parnate) Fluvoxamine (Luvox) Paroxetine (Paxil) Other antidepressant medicines: Bupropion (Wellbutrin) Sertraline (Zoloft) Desvenlafaxine (Pristiq) Vilazodone (Viibryd) Duloxetine (Cymbalta) TCAs (tricyclic medicines): Maprotiline (Ludiomil) Amitriptyline (Elavil) Mirtazapine (Remeron) Amoxapine (Asendin) Nefazodone (Serzone) Clomipramine (Anafranil) Olanzapine/fluoxetine (Symbyax) Desipramine (Norpramin) Trazodone (Desyrel) Doxepin (Sinequan) Venlafaxine (Effexor) Imipramine (Tofranil) Nortriptyline (Pamelor) Perphenazine/amitriptyline (Etrafon) Protriptyline (Vivactil) Trimipramine (Surmntil) What does this medicine do? - Reduces symptoms of depression - Reduces anxiety - Treats diabetic nerve pain - Controls obsessive compulsive disorder (OCD) How do I take this medicine? - Antidepressants are pills you take by mouth. - Most antidepressants are taken once a day. - Take your pills at the same time or times of the day as your doctor has told you. - Some antidepressants need to be taken with food to avoid stomach upset. Other types should be taken at bedtime because they make you sleepy. If you have any questions, please contact our Health Management Team at 414-266-3173. Page 1 of 2 Antidepressant Medications What are the side effects? - Serious side effects. Seek care immediately if you have any of these problems: - Thoughts of suicide or harming yourself - Extreme agitation - Confusion - Seizures - Common side effects: - Sleepiness - Blurry eyesight - Loose stools (diarrhea) or hard stools (constipation) - Dry mouth - Trouble urinating - Weight changes - Sexual problems - Nervousness - Side effects vary for different types of antidepressants. Ask your doctor if you have any questions about side effects. Do I need to take special steps when taking this medicine? - Do not stop taking this medicine suddenly. If you need to stop, your doctor will tell you how to cut down your dose slowly. - Talk to your doctor before taking NSAIDs (nonsteroidal anti-inflammatory drugs) like ibuprofen or naproxen. - Antidepressants react with many other medicines. Let your doctor know what other medicines you are taking. Tell your doctor if you start a new medicine or herb. - Stay away from strong sunlight and tanning lights. Cover up with clothes or use sunscreen if you need to be in the sun. - Avoid alcohol when taking this medicine. - Do not take more or less of the medicine without talking to your doctor. - Check with your doctor about changes in what you can eat if you take MAOIs. What else should I know? - Do not stop taking your antidepressant without talking to your doctor. - It may take a few weeks before you feel the medicine is working. - Tell your doctor if you are pregnant or plan to become pregnant while taking this medicine. - Ask your doctor before breast feeding your baby if you are taking an antidepressant. - Tell your doctor about any medical problems. This information is general in nature and may not apply to you or your condition. Talk to your doctor or nurse about how to best use this information and how to take care of your medical condition. Be sure to ask your doctor or nurse any questions you might have. This information sheet is not intended to provide or replace professional medical advice, diagnosis, or treatment. If you have any questions, please contact our Health Management Team at 414-266-3173. Page 2 of 2 .
Load more

Recommended publications
  • Vortioxetine (Trintellix) Or Vilazodone (Viibryd)
    Clinical Policy: Polyserotonergic Antidepressants- Vortioxetine (Trintellix) or Vilazodone (Viibryd) Reference Number: AZ.CP.PMN.20 Effective Date: 06.17 Last Review Date: 07.20 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Vortioxetine (Trintellix®) and Vilazodone (Viibryd®) are antidepressants that enhance serotoninergic activity via multiple mechanisms FDA approved indications Trintellix and Viibryd are indicated for the treatment of major depressive disorder. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of Arizona Complete Health Trintellix and Viibryd are medically necessary when the following criteria are met: I. Initial Approval Criteria A. Depression (must meet all): 1. Diagnosis of major depressive disorder (MDD); 2. For Trintellix- age ≥ 18 years and for Viibryd- age ≥ 12 years; 3. Failure of a ≥ 8 week trial of one SSRI at up to maximally indicated doses unless contraindicated or clinically significant adverse effects are experienced; 4. Failure of a ≥ 8 week trial of one SNRI at up to maximally indicated doses unless contraindicated or clinically significant adverse effects are experienced; 5. Failure of one SSRI or SNRI used adjunctively with one of the following: bupropion, mirtazapine, or tricyclic antidepressant (TCA) unless contraindicated 6. Dose of Trintellix does not exceed 20 mg/day (1 tablet/day) or dose of Viibryd does not exceed 40 mg/day (1 tablet/day). Approval duration: 12 months B. Other diagnoses/indications 1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): AZ.CP.PMN.53 for Arizona Medicaid.
    [Show full text]
  • Cambridgeshire and Peterborough Joint Prescribing Group MEDICINE REVIEW
    Cambridgeshire and Peterborough Joint Prescribing Group MEDICINE REVIEW Name of Medicine / Trimipramine (Surmontil®) Class (generic and brand) Licensed indication(s) Treatment of depressive illness, especially where sleep disturbance, anxiety or agitation are presenting symptoms. Sleep disturbance is controlled within 24 hours and true antidepressant action follows within 7 to 10 days. Licensed dose(s) Adults: For depression 50-75 mg/day initially increasing to 150-300 mg/day in divided doses or one dose at night. The maintenance dose is 75-150 mg/day. Elderly: 10-25 mg three times a day initially. The initial dose should be increased with caution under close supervision. Half the normal maintenance dose may be sufficient to produce a satisfactory clinical response. Children: Not recommended. Purpose of Document To review information currently available on this class of medicines, give guidance on potential use and assign a prescribing classification http://www.cambsphn.nhs.uk/CJPG/CurrentDrugClassificationTable.aspx Annual cost (FP10) 10mg three times daily: £6,991 25mg three times daily: £7,819 150mg daily: £7,410 300mg daily: £14,820 Alternative Treatment Options within Class Tricyclic Annual Cost CPCCG Formulary Classification Antidepressant (FP10) Amitriptyline (75mg) Formulary £36 Lofepramine (140mg) Formulary £146 Imipramine (75mg) Non-formulary £37 Clomipramine (75mg) Non-formulary £63 Trimipramine (75mg). TBC £7,819 Nortriptyline (75mg) Not Recommended (pain) £276 Doxepin (150mg) TBC £6,006 Dosulepin (75mg) Not Recommended (NICE DO NOT DO) £19 Dosages are based on possible maintenance dose and are not equivalent between medications Recommendation It is recommended to Cambridgeshire and Peterborough CCG JPG members and through them to local NHS organisations that the arrangements for use of trimipramine are in line with restrictions agreed locally for drugs designated as NOT RECOMMENDED:.
    [Show full text]
  • Schizophrenia Care Guide
    August 2015 CCHCS/DHCS Care Guide: Schizophrenia SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT GOALS ALERTS Minimize frequency and severity of psychotic episodes Suicidal ideation or gestures Encourage medication adherence Abnormal movements Manage medication side effects Delusions Monitor as clinically appropriate Neuroleptic Malignant Syndrome Danger to self or others DIAGNOSTIC CRITERIA/EVALUATION (PER DSM V) 1. Rule out delirium or other medical illnesses mimicking schizophrenia (see page 5), medications or drugs of abuse causing psychosis (see page 6), other mental illness causes of psychosis, e.g., Bipolar Mania or Depression, Major Depression, PTSD, borderline personality disorder (see page 4). Ideas in patients (even odd ideas) that we disagree with can be learned and are therefore not necessarily signs of schizophrenia. Schizophrenia is a world-wide phenomenon that can occur in cultures with widely differing ideas. 2. Diagnosis is made based on the following: (Criteria A and B must be met) A. Two of the following symptoms/signs must be present over much of at least one month (unless treated), with a significant impact on social or occupational functioning, over at least a 6-month period of time: Delusions, Hallucinations, Disorganized Speech, Negative symptoms (social withdrawal, poverty of thought, etc.), severely disorganized or catatonic behavior. B. At least one of the symptoms/signs should be Delusions, Hallucinations, or Disorganized Speech. TREATMENT OPTIONS MEDICATIONS Informed consent for psychotropic
    [Show full text]
  • THE USE of MIRTAZAPINE AS a HYPNOTIC O Uso Da Mirtazapina Como Hipnótico Francisca Magalhães Scoralicka, Einstein Francisco Camargosa, Otávio Toledo Nóbregaa
    ARTIGO ESPECIAL THE USE OF MIRTAZAPINE AS A HYPNOTIC O uso da mirtazapina como hipnótico Francisca Magalhães Scoralicka, Einstein Francisco Camargosa, Otávio Toledo Nóbregaa Prescription of approved hypnotics for insomnia decreased by more than 50%, whereas of antidepressive agents outstripped that of hypnotics. However, there is little data on their efficacy to treat insomnia, and many of these medications may be associated with known side effects. Antidepressants are associated with various effects on sleep patterns, depending on the intrinsic pharmacological properties of the active agent, such as degree of inhibition of serotonin or noradrenaline reuptake, effects on 5-HT1A and 5-HT2 receptors, action(s) at alpha-adrenoceptors, and/or histamine H1 sites. Mirtazapine is a noradrenergic and specific serotonergic antidepressive agent that acts by antagonizing alpha-2 adrenergic receptors and blocking 5-HT2 and 5-HT3 receptors. It has high affinity for histamine H1 receptors, low affinity for dopaminergic receptors, and lacks anticholinergic activity. In spite of these potential beneficial effects of mirtazapine on sleep, no placebo-controlled randomized clinical trials of ABSTRACT mirtazapine in primary insomniacs have been conducted. Mirtazapine was associated with improvements in sleep on normal sleepers and depressed patients. The most common side effects of mirtazapine, i.e. dry mouth, drowsiness, increased appetite and increased body weight, were mostly mild and transient. Considering its use in elderly people, this paper provides a revision about studies regarding mirtazapine for sleep disorders. KEYWORDS: sleep; antidepressive agents; sleep disorders; treatment� A prescrição de hipnóticos aprovados para insônia diminuiu em mais de 50%, enquanto de antidepressivos ultrapassou a dos primeiros.
    [Show full text]
  • (Viibryd©) Vilazodone
    3/28/2013 ANTIDEPRESSANT UPDATE: What’s New? The Cardiac Debate The Efficacy Debate ?Pharmacogenomics? WHAT’S NEW Rex S. Lott, Pharm.D., BCPP Professor, ISU College of Pharmacy Short Answer???? Mental Health Clinical Pharmacist, Boise VAMC Clinical Associate Professor, University of Washington, School of Medicine, Department of Psychiatry & Behavioral Sciences Vilazodone (Viibryd ©) Vilazodone - Dosing • Initiate at 10 mg/day X 7days, then 20 • SSRI with partial agonist activity at 5HT 1A mg/day X 7 days receptors. • Target dose = 40 mg/day • Pharmacology of buspirone “built in” • Reduce dose by 50% if co-medication with • CYP3A4 Substrate potent CYP3A4 inhibitors (ketoconazole, • No clinically significant CYP inhibition some macrolide antibiotics) • QD dosing – 25 hour half-life 1 3/28/2013 Ketamine Vilazodone – Pluses / Minuses • NMDA Receptor Antagonist • Potential Pluses: – Less sexual dysfunction than other SSRI’s? • THEORY: – Enhanced anti-anxiety activity (NOT FDA – NMDA Antagonism ↑ Glutamate release labeled for anxiety)? (?compensatory?) • Potential Minuses: Still an SSRI – Stimulation of AMPA glutamate receptors, AND – Repair / regeneration of glutamate-related – GI side effects circuits. – Sleep disturbance – Cost Ketamine Ketamine – Relevant PK • T = ~ 2.5 hours • IV Sub-anesthetic doses 1/2 – 0.5 mg/kg IV infused over ~40 min • Distribution T 1/2 = ~ 10 min – One study of repeated doses (6) • Hepatic Metabolism: CYP 450 • RAPID (hours) remission of depression – 2B6, 3A4 symptoms in treatment-resistant patients – 2C9 (minor)
    [Show full text]
  • NDA/BLA Multi-Disciplinary Review and Evaluation NDA 022567/S021 Viibryd (Vilazodone Hydrochloride)
    NDA/BLA Multi-disciplinary Review and Evaluation NDA 022567/s021 Viibryd (vilazodone hydrochloride) NDA/BLA Multi-Disciplinary Review and Evaluation Application Type Efficacy Supplement Application Number(s) NDA 22567/s021 Priority or Standard Priority Submit Date(s) 08/01/2019 Received Date(s) 08/01/2019 PDUFA Goal Date 02/01/2020 Division/Office Division of Psychiatry (DP)/Office of Neuroscience Review Completion Date 1/31/2020 Established/Proper Name Vilazodone hydrochloride (Proposed) Trade Name Viibryd Pharmacologic Class Selective Serotonin Reuptake Inhibitor Code name N/A Applicant Allergan Sales, LLC Dosage form 10 mg, 20 mg, and 40 mg tablets Applicant proposed Dosing 20 mg to 40 mg once daily with food Regimen Applicant Proposed Major Depressive Disorder (MDD) Indication(s)/Population(s) Applicant Proposed 370143000 SNOMED CT Indication Disease Term for each Proposed Indication Recommendation on Approval Regulatory Action Recommended Major Depressive Disorder (MDD) in adults Indication(s)/Population(s) (if applicable) Recommended SNOMED 370143000 CT Indication Disease Term for each Indication (if applicable) Recommended Dosing 20 mg to 40 mg once daily with food Regimen 1 Version date: July 7, 2019 Reference ID: 4555170 NDA/BLA Multi-disciplinary Review and Evaluation NDA 022567/s021 Viibryd (vilazodone hydrochloride) Table of Contents Table of Tables ................................................................................................................................ 4 Table of Figures ..............................................................................................................................
    [Show full text]
  • Repeated Lysergic Acid Diethylamide in an Animal Model of Depression
    JOP0010.1177/0269881114531666Journal of PsychopharmacologyBuchborn et al. 531666research-article2014 Original Paper Repeated lysergic acid diethylamide in an animal model of depression: Normalisation of learning behaviour and Journal of Psychopharmacology 2014, Vol. 28(6) 545 –552 hippocampal serotonin 5-HT signalling © The Author(s) 2014 2 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0269881114531666 jop.sagepub.com Tobias Buchborn, Helmut Schröder, Volker Höllt and Gisela Grecksch Abstract A re-balance of postsynaptic serotonin (5-HT) receptor signalling, with an increase in 5-HT1A and a decrease in 5-HT2A signalling, is a final common pathway multiple antidepressants share. Given that the 5-HT1A/2A agonist lysergic acid diethylamide (LSD), when repeatedly applied, selectively downregulates 5-HT2A, but not 5-HT1A receptors, one might expect LSD to similarly re-balance the postsynaptic 5-HT signalling. Challenging this idea, we use an animal model of depression specifically responding to repeated antidepressant treatment (olfactory bulbectomy), and test the antidepressant-like properties of repeated LSD treatment (0.13 mg/kg/d, 11 d). In line with former findings, we observe that bulbectomised rats show marked deficits in active avoidance learning. These deficits, similarly as we earlier noted with imipramine, are largely reversed by repeated LSD administration. Additionally, bulbectomised rats exhibit distinct anomalies of monoamine receptor signalling in hippocampus and/or frontal cortex; 35 from these, only the hippocampal decrease in 5-HT2 related [ S]-GTP-gamma-S binding is normalised by LSD. Importantly, the sham-operated rats do not profit from LSD, and exhibit reduced hippocampal 5-HT2 signalling. As behavioural deficits after bulbectomy respond to agents classified as antidepressants only, we conclude that the effect of LSD in this model can be considered antidepressant-like, and discuss it in terms of a re-balance of hippocampal 5-HT2/5-HT1A signalling.
    [Show full text]
  • Medication: Trazodone (Desyrel) 50 Mg
    Trazodone COMPLEX CHRONIC DISEASES PROGRAM Medication Handout Date: May 15, 2018 Medication: Trazodone 50 mg What is trazodone: Trazodone is an antidepressant that is now used for insomnia; it helps with both falling asleep and staying asleep. Expected Benefit: As a sleep aid, you should notice a benefit on the first night within about 30 minutes of taking the medication. Watch for possible side effects: This list of side effects is important for you to be aware of however, it is also important to remember that not all side effects happen to everyone. If you have problems with these side effects talk with your doctor or pharmacist: Hangover effect (drowsiness that continues after waking up in the morning) Dizziness Dry mouth Headache Nausea Stopping the medication: Stopping trazodone is not usually a problem as there is no withdrawal effect you are taking it regularly at higher doses than prescribed below. Please ask your doctor or pharmacist before stopping the medication. Rebound insomnia is not usually a problem which makes trazodone a good option for taking a sleeping aid as needed How to use this medication: Take this medication with or without food Dosing Schedule: Start with 12.5 mg (¼ tablet) or 25 mg (½ tablet) at bedtime Increase the dose by ¼ or ½ a tablet every night until: o You can fall asleep, and/or o Stay asleep The usual effective dose is 50 – 150 mg at bedtime (1 – 3 tablets) Do not continue increasing the dose if you experience a hangover effect Talk with your doctor if you are still having problems with sleep, as you may need a different medication.
    [Show full text]
  • Trazodone Is Not As Effective As Other Antidepressants in Treating a Patient with Major Depressive Disorder
    Case Report Taiwanese Journal of Psychiatry (Taipei) Vol. 26 No. 4 2012 • 311 • Trazodone Is Not as Effective as Other Antidepressants in Treating a Patient with Major Depressive Disorder Kah Kheng Goh, M.D.1, Weng-Kin Tam, M.D.1, Winston W. Shen, M.D.1, 2* Background: Trazodone in clinical use is ineffective because of its sed ation to let patient receive an adequate dose for treating a patient with major depressive disorder. We are report a case report to demonstrate this clinical effi cacy issue in the treatment with trazodone. Case Report: A 83-year old male Taiwanese patient had suffered from MDD for six months. He did not response to the treatment of trazodone 150 mg/day for four months, but consequently, he responded to the treatment of milnacipran 100 mg/day or mirtazapine 30 mg/day. Conclusion: Psy- chiatrists in Taiwan should be alert to the fact that trazodone is not as effective as other antidepressants, and that trazodone should not be prescribed as a single anti- depressant in treating an MDD patient. Key words: antidepressant therapy, suicide, venlafaxine, bupropion (Taiwanese Journal of Psychiatry [Taipei] 2012; 26: 311-5) guideline in the paragraph in describing individu- Introduction al drug trazodone also indicates “other investiga- tors found trazodone to be less effective than other The practice guideline of the American antidepressant medications” [1]. In this case re- Psychiatric Association in the paragraph of intro- port here, we are reporting a case of a major de- ducing antidepressants states “Although some pressive disorder (MDD) patient, who did not re- studies have suggested superiority of one mecha- spond to daily dose of 150 mg of trazodone, but nism of action over another, there are no replica- responded well to antidepressants 100 mg of mil- ble or robust fi ndings to establish a clinically nacipran per day and maybe 30 mg of mirtazapine meaningful difference.
    [Show full text]
  • The Effect of Vortioxetine on Penicillin-Induced Epileptiform
    https://doi.org/10.1590/0004-282X20190064 ARTICLE The effect of vortioxetine on penicillin-induced epileptiform activity in rats O efeito da vortioxetina sobre a atividade epileptiforme induzida pela penicilina em ratos Muhammed Nur ÖGÜN1, Ayhan ÇETİNKAYA2, Ersin BEYAZÇİÇEK3 ABSTRACT Vortioxetine is a multimodal antidepressant agent that modulates 5-HT receptors and inhibits the serotonin transporter. It is indicated especially in cases of major depressive disorder related to cognitive dysfunction. There are many studies investigating the effects of antidepressants on the seizure threshold and short-term epileptic activity. However, the effect of vortioxetine on epileptic seizures is not exactly known. Our aim was to investigate the effects of vortioxetine on penicillin-induced epileptiform activity. Twenty-seven Wistar rats were divided into three groups: sham-control group, positive control group (diazepam), and vortioxetine group. After a penicillin- induced epilepsy model was formed in each of the three groups of animals, 0.1 ml of saline was administered to the control group, 0.1 ml (10 mg/kg) vortioxetine was administered in the vortioxetine group, and 0.1 mL (5 mg/kg) of diazepam was administered in the positive control group, intraperitoneally. The epileptic activity records were obtained for 120 minutes after the onset of seizure. There was no significant difference in spike wave activity between the vortioxetine and diazepam groups, whereas this was significantly reduced in the vortioxetine group compared with the controls. The administration of vortioxetine at a dose of 10 mg/kg immediately after the seizure induction significantly decreased the spike frequencies of epileptiform activity compared with the control group.
    [Show full text]
  • Psychotropic Medications Judicial Reference Guide
    PSYCHOTROPIC MEDICATIONS JUDICIAL REFERENCE GUIDE (Revised Edition 7/15/10) PSYCHOTROPIC MEDICATIONS JUDICIAL REFERENCE GUIDE FIRST EDITION THE STEERING COMMITTEE ON FAMILIES AND CHILDREN IN THE COURT Distributed by Florida Supreme Court 500 South Duval Street Tallahassee, FL 32399-1900 (850) 488-0125 INTRODUCTION One of the toughest challenges facing our dependency courts is the mental health of our children. “In July 2003, the Florida Statewide Advocacy Council published a Red Item Report finding 55% of foster children…in the state of Florida had been put on powerful mind altering psychotropic drugs.”1 In order to assist in this regard, the Psychotherapeutic Medication Subcommittee of the Steering Committee on Families and Children in the Court of the Supreme Court of Florida compiled this resource guide to help judges have a better understanding of psychotropic medications and their interaction with other drugs and with mental health disorders. Recently, the tragic case of Gabriel Myers in 2009 highlighted the fact that a number of child deaths were linked to the off label use of anti-psychotic medications. This is of special concern to Dependency Judges who are ultimately responsible for children in Florida’s Foster Care system. The researchers used publically available data from the internet, FDA manufactures’ published guidelines, publically available non-copyrighted articles and Dr. Brenda Thompson graciously prepared the Psychotropic Medication Chart. Special thanks to Dr. Brenda Thompson, the Honorable Herbert J. Baumann, the Honorable Ralph C. Stoddard, General Magistrate Tracy Ellis, Avron Bernstein, Selena Schoonover, Daniel Ringhoff, Jovasha Lang and to the Members of the Psychotherapeutic Medication Subcommittee.
    [Show full text]
  • Decomposition Profile Data Analysis of Multiple Drug Effects Identifies
    www.nature.com/scientificreports OPEN Decomposition profle data analysis of multiple drug efects identifes endoplasmic reticulum stress‑inducing ability as an unrecognized factor Katsuhisa Morita1,2, Tadahaya Mizuno1,2* & Hiroyuki Kusuhara1* Chemicals have multiple efects in biological systems. Because their on‑target efects dominate the output, their of‑target efects are often overlooked and can sometimes cause dangerous adverse events. Recently, we developed a novel decomposition profle data analysis method, orthogonal linear separation analysis (OLSA), to analyse multiple efects. In this study, we tested whether OLSA identifed the ability of drugs to induce endoplasmic reticulum (ER) stress as a previously unrecognized factor. After analysing the transcriptome profles of MCF7 cells treated with diferent chemicals, we focused on a vector characterized by well‑known ER stress inducers, such as ciclosporin A. We selected fve drugs predicted to be unrecognized ER stress inducers, based on their inducing ability scores derived from OLSA. These drugs actually induced X‑box binding protein 1 splicing, an indicator of ER stress, in MCF7 cells in a concentration‑dependent manner. Two structurally diferent representatives of the fve test compounds exhibited similar results in HepG2 and HuH7 cells, but not in PXB primary hepatocytes derived from human‑liver chimeric mice. These results indicate that our decomposition strategy using OLSA uncovered the ER stress‑inducing ability of drugs as an unrecognized efect, the manifestation of which depended on the background of the cells. Small compounds have the capacity to interact with multiple cellular proteins, thereby mediating multiple efects depending on their exposure to interacting proteins. It is quite difcult to identify the full range of efects of a new chemical, even for its developers, and some factors may be unrecognized.
    [Show full text]